Recombinant phenotyping of cytomegalovirus sequence variants detected after 200 or 100 days of valganciclovir prophylaxis.
about
Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipientsPre-emptive treatment for cytomegalovirus viraemia to prevent cytomegalovirus disease in solid organ transplant recipientsPhenotypic diversity of cytomegalovirus DNA polymerase gene variants observed after antiviral therapy.The biology of cytomegalovirus drug resistanceSurveillance of γδ T Cells Predicts Cytomegalovirus Infection Resolution in Kidney TransplantsPhenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial.Recombinant phenotyping of cytomegalovirus UL54 mutations that emerged during cell passages in the presence of either ganciclovir or foscarnet.Differentiated Levels of Ganciclovir Resistance Conferred by Mutations at Codons 591 to 603 of the Cytomegalovirus UL97 Kinase Gene.Cytomegalovirus UL97 kinase catalytic domain mutations that confer multidrug resistance.Analysis of Mutations in the Gene Encoding Cytomegalovirus DNA Polymerase in a Phase 2 Clinical Trial of Brincidofovir Prophylaxis.Easier Control of Late-Onset Cytomegalovirus Disease Following Universal Prophylaxis Through an Early Antiviral Immune Response in Donor-Positive, Recipient-Negative Kidney Transplants.Effects on maribavir susceptibility of cytomegalovirus UL97 kinase ATP binding region mutations detected after drug exposure in vitro and in vivo
P2860
Q24200697-E3BEFF70-DD32-4A2A-80EB-B7E4F70EB074Q24200991-9F44B8DA-9779-4209-80FD-80D7010EB7E7Q34687313-6E488176-B4D0-45E6-A98B-984E12FEE3ADQ35684511-DEC9D7F8-5AF0-4470-9584-F0A9C669720FQ36514890-FEF8CF2E-9C7B-42A3-97B2-3A936CC5A39BQ37671946-3935E186-5D9B-49FB-A629-9413EF7E0DD4Q38282979-A2A91BF8-5F10-4155-A28C-3F83D60CC1CCQ38818062-30A22A26-0435-4596-8137-6D3329AEF3E1Q39155340-49715B5F-63C3-4B3C-8192-C18AD416F533Q39949115-A736ACB5-F82A-4CB5-80E1-9705E9A64880Q40763966-30D9289B-891A-4E98-A929-32F554C5FD57Q42141568-41CA781D-32D9-481A-8830-DD399BD218D5
P2860
Recombinant phenotyping of cytomegalovirus sequence variants detected after 200 or 100 days of valganciclovir prophylaxis.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
Recombinant phenotyping of cyt ...... of valganciclovir prophylaxis.
@en
Recombinant phenotyping of cyt ...... of valganciclovir prophylaxis.
@nl
type
label
Recombinant phenotyping of cyt ...... of valganciclovir prophylaxis.
@en
Recombinant phenotyping of cyt ...... of valganciclovir prophylaxis.
@nl
prefLabel
Recombinant phenotyping of cyt ...... of valganciclovir prophylaxis.
@en
Recombinant phenotyping of cyt ...... of valganciclovir prophylaxis.
@nl
P2093
P1433
P1476
Recombinant phenotyping of cyt ...... of valganciclovir prophylaxis.
@en
P2093
Gail Marousek
Guy Boivin
Jane A L Ives
Mahdi Farhan
Nathalie Goyette
Robert Elston
Sunwen Chou
P304
P356
10.1097/TP.0B013E3181FDD9D2
P577
2010-12-01T00:00:00Z